Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491788 · ClinicalTrials.gov registry record · Phase 4
Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
A Phase 4 study, sponsored by VA Palo Alto Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02491788 is a Phase 4 study that has completed, run by VA Palo Alto Health Care System. The registered enrollment target is 19 participants.
The verdict
NCT02491788, a Phase 4 study, has completed, sponsored by VA Palo Alto Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
Interventions
- DRUG Placebo
- DRUG Suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02491788
The ClinicalTrials.gov registry entry for NCT02491788 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Palo Alto Health Care System, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02491788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02491788 about?
NCT02491788 is a clinical study titled "Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers". The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and su...
What is the current status of trial NCT02491788?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2016-02-01. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT02491788?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT02491788?
This trial is sponsored by VA Palo Alto Health Care System, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.